Abstract 5710
Background
Merkel cell carcinoma (MCC) is a rare, aggressive tumour of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of various checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is currently the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC). Here, we report the Dutch real-world efficacy data of avelumab in patients with mMCC.
Methods
All mMCC patients from 4 tertiary referral centres in the Netherlands from December 2016 were analysed. Patients were included in this analysis if they had received avelumab for mMCC, regardless of other previous lines of therapy. Patient data were collected retrospectively and followed up prospectively after initiation of data collection. Primary endpoints were response rate (RR) and duration of response (DOR) , secondary endpoints were progression free survival (PFS), overall survival (OS) and toxicity. Toxicity was evaluated according to CTCAE version 5.0.
Results
Forty-six patients received avelumab, of which 37 patients were evaluable for response (9 had not reached response evaluation, 1 died due to comorbidity). In 22 (59.5%) patients avelumab was first-line treatment. Median follow up time was 7.8 (IQR 3.7-10.1) months. RR was 59.5% (n = 22) with 21.6% (n = 8) of patients having a complete radiological response. Median DOR was 6.3 (IQR 3.0-12.5) months and 15 (40.5%) patients had ongoing response at time of data analysis. Median PFS was 12.2 (95% CI 3.3-21.1) months, median OS was not yet reached. In subgroup analysis no differences were found for the presence of visceral metastases at baseline or previous lines of therapy. Five (13.2%) patients experienced grade 3 toxicity, of which 2 (4.3%) patients discontinued avelumab. No grade 4-5 toxicity were seen.
Conclusions
In the Netherlands treatment with avelumab is increasingly used in first- and second-line treatment for mMCC. In this real-world cohort, RR, DOR, PFS and toxicity results were in line with results from clinical trials and show relatively high, durable responses in patients with mMCC, unaffected by the presence of visceral metastases or previous lines of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5678 - Nanomaterials Augmented LDI-TOF-MS for Hepatocellular Carcinoma Diagnosis and Classification
Presenter: Jian Zhou
Session: Poster Display session 3
Resources:
Abstract
2436 - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples
Presenter: Hua Dong
Session: Poster Display session 3
Resources:
Abstract
5271 - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching
Presenter: Zhaohui Jin
Session: Poster Display session 3
Resources:
Abstract
4787 - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system
Presenter: Suthida Suwanvecho
Session: Poster Display session 3
Resources:
Abstract
5744 - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care
Presenter: Joe Thompson
Session: Poster Display session 3
Resources:
Abstract
3752 - The association between wearable device physical activity metrics and performance status in oncology: a systematic review
Presenter: Milan Kos
Session: Poster Display session 3
Resources:
Abstract
5820 - SomaticNET: neural network evaluation of somatic mutations in cancer
Presenter: Geoffroy Dubourg-Felonneau
Session: Poster Display session 3
Resources:
Abstract
4771 - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.
Presenter: Mauricio Ribeiro
Session: Poster Display session 3
Resources:
Abstract
1209 - Metastatic Cancer Whole-Exome Sequencing in daily practice
Presenter: Manon Réda
Session: Poster Display session 3
Resources:
Abstract
5702 - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study
Presenter: Haitao Wang
Session: Poster Display session 3
Resources:
Abstract